GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

by | Oct 19, 2026 | Clinical Trials | 0 comments

​ Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: GI-102; Drug: Pasritamig

Sponsors: GI Innovation, Inc.; Janssen Research & Development, LLC

Recruiting Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Drug: GI-102; Drug: Pasritamig
Sponsors: GI Innovation, Inc.; Janssen Research & Development, LLC
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *